Unknown

Dataset Information

0

Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B.


ABSTRACT:

Background/aims

This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB).

Methods

We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated.

Results

The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15×gender [female=0 / male=1]+23×cirrhosis [absence=0 / presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001).

Conclusions

The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naïve CHB patients receiving entecavir.

SUBMITTER: Sohn W 

PROVIDER: S-EPMC5497662 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.

Sohn Won W   Cho Ju-Yeon JY   Kim Ji Hoon JH   Lee Jung Il JI   Kim Hyung Joon HJ   Woo Min-Ah MA   Jung Sin-Ho SH   Paik Yong-Han YH  

Clinical and molecular hepatology 20170516 2


<h4>Background/aims</h4>This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB).<h4>Methods</h4>We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validat  ...[more]

Similar Datasets

| S-EPMC4998368 | biostudies-literature
| S-EPMC8126482 | biostudies-literature
| S-EPMC8042481 | biostudies-literature
| S-EPMC8371628 | biostudies-literature
| S-EPMC5216979 | biostudies-literature
| S-EPMC6893130 | biostudies-literature
| S-EPMC5803697 | biostudies-literature
| S-EPMC4040722 | biostudies-literature
| S-EPMC7206589 | biostudies-literature
| S-EPMC6699129 | biostudies-literature